Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Angers – page 33

681 clinical trials in Angers, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Angers at a glance
681
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

681 trials in Angers

Open in trial search

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study on the Effectiveness and Safety of Lanifibranor for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis Stages F2/F3

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lanifibranor
  • Sponsor:Inventiva

Hot flush

Not recruiting

Study of Fezolinetant for Hot Flashes in Women with Hormone Receptor-Positive Breast Cancer Receiving Hormone Therapy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fezolinetant
  • Sponsor:Astellas Pharma Global Development Inc.

Diffuse large B-cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Polatuzumab Vedotin, Rituximab, and CHP in Patients with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Polatuzumab Vedotin
  • Sponsor:F. Hoffmann-La Roche AG

Hormone receptor positive breast cancer+1

Not recruiting

Study Comparing DB-1303 and Chemotherapy for Patients with HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Dualitybio Inc.

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study of resmetirom (MGL-3196) in patients with Non-Alcoholic Steatohepatitis (NASH) to prevent liver damage and disease progression

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Resmetirom
  • Sponsor:Madrigal Pharmaceuticals Inc.

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study on the Effects of Semaglutide in Patients with Non-Alcoholic Steatohepatitis (NASH) and Fibrosis Stages 2 or 3

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study on the Effectiveness of NNC0194-0499 and Semaglutide in Treating Non-Alcoholic Steatohepatitis (NASH) in Patients with Fibrosis Stages 2-4

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Non-small cell lung cancer

Not recruiting

Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Breast cancer

Not recruiting

Study of Pembrolizumab and Chemotherapy for Patients with HR+/HER2- Advanced Breast Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Metastatic renal cell carcinoma

Not recruiting

Study of Pembrolizumab and Axitinib Combination Versus Sunitinib for Patients with Advanced or Metastatic Kidney Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Merck Sharp & Dohme LLC

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Breast cancer

Not recruiting

Study of Camizestrant plus Ribociclib as First‑Line Treatment for Patients with ER‑Positive, HER2‑Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Angers

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on multiple myeloma, breast cancer, and various forms of lung cancer. Studies are evaluating new combination therapies and treatment approaches for both early-stage and advanced cancers.

  • Triple-negative breast cancer treatments
  • Advanced non-small cell lung cancer therapies
  • Head and neck squamous cell carcinoma studies

Research includes investigation of novel drug combinations and immunotherapy approaches.

02 Cardiovascular Studies

Clinical research addressing heart failure prevention and acute myocardial infarction management. Studies are exploring innovative pain management approaches and preventive treatments.

  • Heart failure risk reduction
  • Pulmonary hypertension treatments
  • Emergency cardiac care interventions

Focus on both acute care solutions and long-term prevention strategies.

03 Immunology and Transplantation

Comprehensive research in kidney transplantation and immune disorders, including studies on preventing rejection and managing immunosuppression.

  • Transplant rejection prevention
  • Immune response monitoring
  • Novel immunotherapy approaches

Trials aim to improve long-term outcomes for transplant recipients and immune disorder patients.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.